Nanobiotix S.A.
0QAV.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.2B
Close$
$-7.66
139.6% downside
Current Fair Value
139.6% downsideOvervalued by 139.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 0.57 |
| Outstanding Shares | 48,883,075 |
Return
| Return on Equity | 314.58% |
|---|---|
| Return on Assets | -81.83% |
| Return on Invested Capital | -165.35% |
Valuation & Multiples
| P/E Ratio | -19.31 |
|---|---|
| PEG | -3.54 |
| Price to Sales | - |
| Price to Book Ratio | -19.37 |
| Enterprise Value to Revenue | 98.9 |
| Enterprise Value to EBIT | -17.55 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -4.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 29, 2026
EPS Estimate
$-0.42
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationNext Earnings Call
Expected Date
April 27, 2027
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$23.62 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanobiotix
89 employees
CEO: Laurent Levy Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of cry...